Interest expense for the three months ended
The change in fair value of derivative liability is related to the embedded conversion feature in the Series B convertible preferred stock. The valuation of the derivative liability is dependent upon a number of factors beyond our control. As such, the amount of other income or expense that we report related to the change in the fair value of the derivative liability is somewhat unpredictable, but may be significant, and will continue to be reported until the holders of the Series B convertible preferred stock have converted their shares into shares of our common stock.
Net Loss. Net loss for the three months ended
Nine Months Ended
Revenue. Total revenue for the nine months ended
Operating Expenses. Total operating expenses for the nine months ended
As described in more detail above, a significant portion of the decrease in stock-based compensation relates to the options granted by our subsidiary, Xenogenics and the decrease between the two periods relates to the vesting patterns of the options granted and the number of options that are vested in each period.
The decrease in shareholder meeting expense relates to the timing of the 2012 meeting (
The decrease in legal and accounting expense relates principally to a reduction in patent-related legal costs incurred primarily by our subsidiary Xenogenics related to Ideal BioStent™ as a result of less patent-related legal work related to the stent during the nine months ended
The increase in consulting and contract services is primarily related to costs of